2. Search Result
Search Result
Results for "

glucocorticoid receptor antagonist

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

5

Natural
Products

8

Isotope-Labeled Compounds

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15709
    AL 082D06
    4 Publications Verification

    D06; D-06

    		 Glucocorticoid Receptor Endocrinology
    AL 082D06 is a selective, nonsteroidal glucocorticoid receptor (GR) antagonist with Ki of 210 nM.
    AL 082D06
  • HY-15710
    Cort108297

    		Glucocorticoid Receptor Metabolic Disease Endocrinology
    Cort108297 is a specific glucocorticoid receptor (GR) antagonist. Cort108297 has a high affinity for GRs with a Ki of 0.45 nM.
    Cort108297
  • HY-13683
    Mifepristone
    Maximum Cited Publications
    60 Publications Verification

    RU486; RU 38486

    		 Endogenous Metabolite Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy Endocrinology Cancer
    Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC50s of 0.2 nM and 2.6 nM in in vitro assay .
    Mifepristone
  • HY-159695A
    IONIS-GCCRRx sodium

    ISIS 426115 sodium

    		 Glucocorticoid Receptor Metabolic Disease
    IONIS-GCCRRx (ISIS 426115) sodium, a glucocorticoid receptor antagonist, is a 2'-O-methoxyethyl (2'-MOE) antisense oligonucleotide (ASO) .
    IONIS-GCCRRx sodium
  • HY-159695
    IONIS-GCCRRx

    ISIS 426115

    		 Glucocorticoid Receptor Metabolic Disease
    IONIS-GCCRRx (ISIS 426115), a glucocorticoid receptor antagonist, is a 2'-O-methoxyethyl (2'-MOE) antisense oligonucleotide (ASO) .
    IONIS-GCCRRx
  • HY-13702
    Nilutamide

    Nilandron; RU 23908

    		 Androgen Receptor Parasite Infection Endocrinology Cancer
    Nilutamide (Nilandron) is an orally active nonsteroidal androgen receptor antagonist with affinity for androgen receptors but not for progestogen, estrogen or glucocorticoid receptors. Nilutamide can be used to research prostate cancer. Nilutamide also has antischistosomal properties .
    Nilutamide
  • HY-125627
    CP-394531

    		Glucocorticoid Receptor Androgen Receptor Neurological Disease Metabolic Disease
    CP-394531 is an efficient and highly selective non-steroidal glucocorticoid receptor (GR) antagonist, with a Ki value of 0.1 nM. CP-394531 has a weak binding to androgen receptor (AR) (Ki = 130 nM), and has almost no effect on progesterone receptor (PR) and estrogen receptors (ERα, ERβ). CP-394531 completely blocks the half-maximal agonistic effect induced by Dexamethasone (HY-14648G), with a Kif of 4.1 nM. CP-394531 can be used to study various diseases such as diabetes, obesity, depression, neurodegenerative diseases, glaucoma and Cushing's disease .
    CP-394531
  • HY-117847
    LLY-2707

    		Glucocorticoid Receptor Neurological Disease Metabolic Disease
    LLY-2707 is a selective glucocorticoid receptor (GR) antagonist. LLY-2707 is promising for research of diabetes and psychiatric disorders such as schizophrenia .
    LLY-2707
  • HY-167932
    Mifepristone methochloride

    RU486 methochloride; RU 38486 methochloride

    		 Progesterone Receptor Endocrinology
    Mifepristone (RU486) methochloride is a glucocorticoid antagonist that blocks peripheral glucocorticoid and progesterone receptors. Mifepristone methochloride has been shown to have minimal effects on intraocular pressure in treated rabbits. Mifepristone methochloride was developed as a water-soluble formulation to enhance ocular penetration of the drug.
    Mifepristone methochloride
  • HY-120016
    RU 43044

    		Glucocorticoid Receptor Neurological Disease
    RU 43044 is a glucocorticoid receptor antagonist. RU 43044 shows an antidepressant-like effect, probably via an inhibition of enhanced prefrontal dopaminergic neurotransmission in these mouse models .
    RU 43044
  • HY-125839
    OP-3633

    		Glucocorticoid Receptor Inflammation/Immunology Endocrinology
    OP-3633 is a potent and selective steroidal glucocorticoid receptor (GR) antagonist with an IC50 of 29 nM, with inhibition of GR transcriptional activity. OP-3633 exhibits low progesterone receptor (PR) agonism and androgen receptor (AR) antagonism .
    OP-3633
  • HY-13683S
    Mifepristone-d3

    RU486-d3; RU 38486-d3

    		 Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy Endocrinology Cancer
    Mifepristone-d3 is the deuterium labeled Mifepristone. Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC50s of 0.2 nM and 2.6 nM in in vitro assay .
    Mifepristone-d3
  • HY-117880
    Exicorilant
    2 Publications Verification

    CORT 125281

    		 Glucocorticoid Receptor Metabolic Disease Endocrinology
    Exicorilant (CORT 125281) is a selective and oral active glucocorticoid receptor (GR) antagonist, with a Ki value of 7 nM . Exicorilant (CORT 125281) has potential to overcome adiposity, glucose intolerance and dyslipidaemia .
    Exicorilant
  • HY-13683S2
    Mifepristone-d6

    RU486-d6; RU 38486-d6

    		 Glucocorticoid Receptor Autophagy Endogenous Metabolite NO Synthase Progesterone Receptor Isotope-Labeled Compounds Endocrinology Cancer
    Mifepristone-d6 is deuterated labeled Mifepristone (HY-13683). Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC50s of 0.2 nM and 2.6 nM in in vitro assay .
    Mifepristone-d6
  • HY-13683R
    Mifepristone (Standard)
    Maximum Cited Publications
    60 Publications Verification

    RU486 (Standard); RU 38486 (Standard)

    		 Reference Standards Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy Endocrinology Cancer
    Mifepristone (Standard) is the analytical standard of Mifepristone. This product is intended for research and analytical applications. Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC50s of 0.2 nM and 2.6 nM in in vitro assay .
    Mifepristone (Standard)
  • HY-125558
    PT150

    ORG-34517

    		 Glucocorticoid Receptor Neurological Disease
    PT150 (ORG-34517) is a competitive and orally active glucocorticoid receptor antagonist. PT150 shows neuroprotective effects. PT150 has the potential for the research of Parkinson’s disease .
    PT150
  • HY-111372A
    (Rac)-Finerenone

    (Rac)-BAY 94-8862

    		 Mineralocorticoid Receptor Cardiovascular Disease
    (Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold) .
    (Rac)-Finerenone
  • HY-13702R
    Nilutamide (Standard)

    Nilandron (Standard); RU 23908 (Standard)

    		 Reference Standards Androgen Receptor Parasite Infection Endocrinology Cancer
    Nilutamide (Standard) is the analytical standard of Nilutamide. This product is intended for research and analytical applications. Nilutamide (Nilandron) is an orally active nonsteroidal androgen receptor antagonist with affinity for androgen receptors but not for progestogen, estrogen or glucocorticoid receptors. Nilutamide can be used to research prostate cancer. Nilutamide also has antischistosomal properties .
    Nilutamide (Standard)
  • HY-111372
    Finerenone
    5 Publications Verification

    BAY 94-8862

    		 Mineralocorticoid Receptor Cardiovascular Disease
    Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone
  • HY-112710
    ORIC-101

    		Glucocorticoid Receptor Endocrinology Cancer
    ORIC-101 is a highly potent and selective glucocorticoid receptor antagonist, with an EC50 of 5.6 nM. Anti-cancer activity. ORIC-101 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    ORIC-101
  • HY-B0251S
    Eplerenone-d3

    Epoxymexrenone-d3

    		 Isotope-Labeled Compounds Mineralocorticoid Receptor Endogenous Metabolite Cardiovascular Disease
    Eplerenone-d3 is the deuterium labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, competitive and oreally active aldosterone antagonist with an IC50 of 138 nM. Eplerenone has low affinity for progesterone, androgen, estrogen and glucocorticoid receptors. Eplerenone can be used for hypertension and heart failure after myocardial infarction reserch .
    Eplerenone-d3
  • HY-111372R
    Finerenone (Standard)

    BAY 94-8862 (Standard)

    		 Reference Standards Mineralocorticoid Receptor Cardiovascular Disease
    Finerenone (Standard) is the analytical standard of Finerenone. This product is intended for research and analytical applications. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone (Standard)
  • HY-111372S
    Finerenone-d3

    BAY 94-8862-d3

    		 Mineralocorticoid Receptor Others
    Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone-d3
  • HY-123163
    JNJ-1250132

    RWJ-66826; RTI-6617-003

    		 Progesterone Receptor Glucocorticoid Receptor Androgen Receptor Estrogen Receptor/ERR Endocrinology Cancer
    JNJ-1250132 (RWJ-66826) is an orally active and potent steroidal progesterone receptor (PR) antagonist, with an IC50 of 1.3 nM. JNJ-1250132 inhibits binding of the receptor to DNA in vitro. JNJ-1250132 is a potent competitive inhibitor of binding to the human glucocorticoid receptor (GR) (IC50=0.50 nM) and the rat androgen receptor (AR) (IC50=5.6 nM), and was a weak inhibitor of binding to human Estrogen receptor (ER) (IC50 >3000 nM) .
    JNJ-1250132
  • HY-111372S1
    Finerenone-d5

    BAY 94-8862-d5

    		 Isotope-Labeled Compounds Mineralocorticoid Receptor Cardiovascular Disease
    Finerenone-d5 (BAY 94-8862-d5) is deuterium labeled Finerenone. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone-d5
  • HY-13683S1
    Mifepristone-13C,d3

    RU486-13C,d3; RU 38486-13C,d3

    		 Isotope-Labeled Compounds Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy Endocrinology Cancer
    Mifepristone- 13C,d3 is the 13C- and deuterium labeled Mifepristone. Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC50s of 0.2 nM and 2.6 nM in in vitro assay . Mifepristone-13C,d3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Mifepristone-13C,d3
  • HY-B0765
    Dehydroepiandrosterone sulfate sodium
    5 Publications Verification

    DHEA sulfate sodium; Prasterone sulfate sodium

    		 GABA Receptor Sigma Receptor iGluR PPAR NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology
    Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) sodium salt is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate sodium salt has both non-competitive antagonist activity of GABAA receptor and agonist activity of σ1 receptor. Dehydroepiandrosterone sulfate sodium salt can partially penetrate the blood-brain barrier, inhibit GABAA receptor-mediated chloride influx, enhance NMDA receptor activity through σ1 receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate sodium salt participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate sodium salt may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .
    Dehydroepiandrosterone sulfate sodium
  • HY-113416
    Dehydroepiandrosterone sulfate
    5 Publications Verification

    DHEA sulfate; Prasterone sulfate

    		 GABA Receptor Sigma Receptor iGluR PPAR NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology
    Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate has both non-competitive antagonist activity of GABAA receptor and agonist activity of σ1 receptor. Dehydroepiandrosterone sulfate can partially penetrate the blood-brain barrier, inhibit GABAA receptor-mediated chloride influx, enhance NMDA receptor activity through σ1 receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .
    Dehydroepiandrosterone sulfate
  • HY-113416AS
    Dehydroepiandrosterone sulfate-d6 sodium dihydrate

    DHEA sulfate-d6 sodium dihydrate; Prasterone sulfate-d6 sodium dihydrate

    		 Isotope-Labeled Compounds GABA Receptor Sigma Receptor iGluR PPAR NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology
    Dehydroepiandrosterone sulfate sodium dihydrate-d6 sodium dihydrate is the deuterium labeled Dehydroepiandrosterone sulfate sodium dihydrate. Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) sodium dihydrate is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate sodium dihydrate has both non-competitive antagonist activity of GABAA receptor and agonist activity of σ1 receptor. Dehydroepiandrosterone sulfate sodium dihydrate can partially penetrate the blood-brain barrier, inhibit GABAA receptor-mediated chloride influx, enhance NMDA receptor activity through σ1 receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate sodium dihydrate participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate sodium dihydrate may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .
    Dehydroepiandrosterone sulfate-d6 sodium dihydrate
  • HY-113416R
    Dehydroepiandrosterone sulfate (Standard)

    DHEA sulfate (Standard); Prasterone sulfate (Standard)

    		 Reference Standards GABA Receptor Sigma Receptor iGluR PPAR NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology
    Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) (Standard) is the analytical standard of Dehydroepiandrosterone sulfate (HY-113416). This product is intended for research and analytical applications. Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate has both non-competitive antagonist activity of GABAA receptor and agonist activity of σ1 receptor. Dehydroepiandrosterone sulfate can partially penetrate the blood-brain barrier, inhibit GABAA receptor-mediated chloride influx, enhance NMDA receptor activity through σ1 receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .
    Dehydroepiandrosterone sulfate (Standard)
  • HY-141921S
    Dehydroepiandrosterone sulfate sodium-d6

    DHEA sulfate sodium-d6; Prasterone sulfate sodium-d6

    		 Isotope-Labeled Compounds GABA Receptor Sigma Receptor iGluR PPAR NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology
    Dehydroepiandrosterone sulfate sodium salt-d6 (DHEA sulfate sodium salt-d6; Prasterone sulfate sodium salt-d6) is the deuterium labeled Dehydroepiandrosterone sulfate sodium salt (HY-B0765). Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) sodium salt is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate sodium salt has both non-competitive antagonist activity of GABAA receptor and agonist activity of σ1 receptor. Dehydroepiandrosterone sulfate sodium salt can partially penetrate the blood-brain barrier, inhibit GABAA receptor-mediated chloride influx, enhance NMDA receptor activity through σ1 receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate sodium salt participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate sodium salt may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .
    Dehydroepiandrosterone sulfate sodium-d6
  • HY-B0765R
    Dehydroepiandrosterone sulfate sodium (Standard)

    DHEA sulfate sodium (Standard); Prasterone sulfate sodium (Standard)

    		 Reference Standards GABA Receptor Sigma Receptor iGluR PPAR NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology
    Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) sodium salt (Standard) is the analytical standard of Dehydroepiandrosterone sulfate sodium salt (HY-B0765). This product is intended for research and analytical applications. Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate has both non-competitive antagonist activity of GABAA receptor and agonist activity of σ1 receptor. Dehydroepiandrosterone sulfate can partially penetrate the blood-brain barrier, inhibit GABAA receptor-mediated chloride influx, enhance NMDA receptor activity through σ1 receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .
    Dehydroepiandrosterone sulfate sodium (Standard)
  • HY-N0910
    Notoginsenoside Ft1
    1 Publications Verification

    		 PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR Cardiovascular Disease Metabolic Disease Cancer
    NotoginsenosideFt1 is a saponin found in Panax notoginseng. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 + T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca 2+ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y12 receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .
    Notoginsenoside Ft1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: